nubeqa
bayer ag - darolutamide - prostata tumörer, kastrering-resistent - endokrin terapi - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
leuprorelin sandoz 3,6 mg implantat
sandoz a/s - leuprorelinacetat - implantat - 3,6 mg - leuprorelinacetat 3,78 mg aktiv substans - leuprorelin
leuprorelin sandoz 5 mg implantat
sandoz a/s - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin cross pharma 5 mg implantat
cross pharma ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin cross pharma 5 mg implantat
cross pharma ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin 2care4 5 mg implantat
2care4 aps - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin pharmachim 5 mg implantat
pharmachim ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprostin 5 mg implantat
medartuum ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans - leuprorelin
leuprorelin 2care4 5 mg implantat
2care4 aps - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans
leuprorelin medartuum 5 mg implantat
medartuum ab - leuprorelinacetat - implantat - 5 mg - leuprorelinacetat 5,25 mg aktiv substans